A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes | MicrobiomeTrials
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2024-12-08Est. Completion: 2026-01-19
Enrollment target: 103 participants
Locations
Alliance for Multispecialty Research, Kansas City, Missouri, United States
Rochester Clinical Research, Rochester, New York, United States
Seattle Clinical Research Center, Seattle, Washington, United States
University of Washington Virology Research Clinic, Seattle, Washington, United States
East Sydney Doctors, Darlinghurst, Australia, Australia
Royal Melbourne Hospital, Parkville, Australia, Australia
Taylor Square Private Clinic, Surry Hills, Australia, Australia
Momentum Clinical Research, Sydney, Australia, Australia
Canopy Clinical Wollongong, Wollongong, Australia, Australia
Momentum Sunshine, Melbourne, Au, Australia
New Zealand Clinical Research, Auckland, New Zealand, New Zealand
New Zealand Clinical Research, Christchurch, New Zealand, New Zealand
Pacific Clinical Research Network, Nelson, New Zealand, New Zealand
Momentum Palmerston North, Palmerston North, New Zealand, New Zealand
Pacific Clinical Research Network, Rotorua, New Zealand, New Zealand
Pacific Clinical Research Network, Upper Hutt, New Zealand, New Zealand
Other microbiome trials you might be interested in